ccretion (amortization) of premium/discount on marketable securities(3)(119)Changes in operating assets and liabilities:Accounts receivable4,011685Inventories(407)3Prepaid expenses and other current assets(971)(261)Other assets(48)(71)Accounts payable1,037(2,720)Accrued compensation(4,324)(2,958)Related party payable-(766)Other accrued liabilities2,570(1,372)Deferred revenues3,856(7,026)Net cash provided by (used in) operating activities7,286(12,025)Investing activities:(Increase) decrease in restricted cash(46)-Purchase of property and equipment(891)(1,320)Purchase of marketable securities(27,104)-Proceeds from maturities of marketable securities-13,610Net cash provided by (used in) investing activities(28,041)12,290Financing activities:Principal payments on financing obligations-(1,339)Payments in preparation for initial public offering-(1,636)Proceeds from exercises of stock options1,485140Net cash provided by (used in) financing activities1,485(2,835)Effect of exchange rate changes on cash and cash equivalents26(18)Net increase in cash and cash equivalents(19,244)(2,588)Cash and cash equivalents: Beginning of the period72,39631,785 End of the period53,15229,197 Marketable securities at the end of period28,83610,067Cash, cash equivalents and marketable securities$
39,264Reconciliation of GAAP to Non-GAAP Financial InformationIn this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.
A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.
Codexis, Inc.Reconciliation of GAAP Net Loss to Adjusted EBITDA(Unaudited)(In Thousands)Three MoPage: 1 2 3 4 5 6 7 Related biology technology :1
. Former Senator Byron Dorgan Elected to Codexis Board2
. Codexis Reports Fourth Quarter and Full Year 2010 Results3
. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook4
. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role5
. Codexis R&D Productivity Panels Also Used By Roche6
. Codexis Names Lori Giver VP Systems Biology7
. Codexis, Teva in Licensing Agreement Final8
. Codexis Names Vice President, Intellectual Property9
. Codexis, Arch Announce Expanded Collaboration10
. Vanda Pharmaceuticals Reports First Quarter 2011 Results11
. Reportlinker Adds Genetics Reports Bundle